Alok A. Khorana, M.D., from the Cleveland Clinic, and colleagues reviewed recent evidence from the ESPAC-4 multicenter, international phase III trial to revise guideline recommendations regarding the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor. The study compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients. Read more . . .
Guidelines relating to the appropriate adjuvant regimen for patients with pancreatic cancer have been updated in light of new evidence, according to a special article published online April 11 in the Journal of Clinical Oncology.